Ala Ali

@WTC2025 congress showcased innovation that is shaping the future of beta-cell replacement therapy. Pancreas and islet transplantation continue to advance rapidly, with major progress in organ preservation, immunosuppression, and regenerative therapies. tinyurl.com/wbtrmwmz

Gene–disease relationships for glomerular phenotypes: expert recommendations from ClinGen dlvr.it/TSfng1

@Kdhchels_ If this is true, why Pedro Neto? Alonso should learn from RM lessons. He should not be preoccupied; he should assess first and then make a wise decision.

🚨𝗡𝗘𝗪: Xabi Alonso has given Blue Co a list of SEVEN players he would SELL immediately after the World Cup as the new Chelsea head manager. The list are: 1. Liam Delap 🏴󠁧󠁢󠁥󠁮󠁧󠁿 2. Robert Sanchez 🇪🇸 3. Alejandro Garnacho 🇦🇷 4. Pedro Neto 🇵🇹 5. Malo Gusto…. see below

Don’t miss this timely seminar today! One correction- Lecture will start at 7pm Egypt time (equivalent to 7 pm KSA and Kuwait time, 8 pm UAE time). The rest of the timezones below (besides Egypt) is correct. Thank you for your patience. @GlomCon

Difficult but good recent teaching case. LM- normal appearing glomeruli but proximal tubules filled with eosinophilic granules. IF- negative. EM- large number of lysosomes, with degenerative changes. Lysozyme stain 3+ positive in proximal tubules. Dx: Lysozyme associated-tubulopathy (myelofibrosis/clinical). Usually see this in patients with CML. D/D: light chain proximal tubulopathy, but IF & pronase IF are negative. 60-yr old with chronic kidney disease, pulmonary nodules, and JAK2+ myelofibrosis. Evaluation showed high levels of serum lysozyme, and lysozymuria.

Differentiating the Trio of Focal Segmental Glomerulosclerosis Causes - MedPage Today - goo.gl/alerts/QfyJty #GoogleAlerts

@ttsorg webinar for clinically relevant information useful for all transplant physicians tts.org/education/tts-… @KottonNelson @HumarAtul @HansHHirsch1

"Anti-nephrin antibodies in pediatric nephrotic syndrome: a new paradigm" (via #pubmedontap) ncbi.nlm.nih.gov/pubmed/42026266

Immune checkpoint inhibitor–associated nephritis—treatment standard 🆓doi.org/10.1093/ndt/gf…

@LegacySiu Alvaro Morara

Guess the player Very Hard

Methamphetamine abuse=severe thrombotic microangiopathy Unfortunate weekend case 😢 Glomeruli: mesangiolysis +++ & ischemic changes Interstitium: Hemorrhage, inflammation & scarring Vessels: Severe sclerosis, thrombosis, schistocytes 40-yr woman, hypertension, AKI, meth abuse

🚨 Update Alert 👉 Immune Complex-Mediated Glomerulonephritis at glompedia.org ICGN represents a broad diagnostic umbrella. This dives into the heterogeneous etiologies characterized by granular immunoglobulin and complement deposition. #GlomCon #Pathology #ICGN

What a great paper by Professor @SethiRenalPath on "Finding the etiology of MPGN" in @Kidney_Int. It emphasizes the growing understanding of this GN pattern and paves the way for more personalized therapy. doi.org/10.1016/j.kint… Summary

Join us tomorrow, April 10, 2026, on a knowledge rollercoaster road to the understanding of Targeted Therapy for C3GN by @GlomerGal Join meeting here: glomcon.zoom.us Meeting ID: 884 4208 1901 Passcode: 100499 Visit us 👉glomcon.org/arabia-glomcon @GlomCon

A Young Man With Nephrotic Syndrome and Facial Rash: A Quiz bit.ly/4cefbQu (FREE) •What further tests are needed to determine the etiology of the rash? •What additional tests can be done? •How would you treat this patient?

Dapagliflozin is not dialyzable and does not accumulate significantly in dialysis patients—supporting biological plausibility for safe use. CME INDIA Clinical Pearls: SGLT2 Inhibitors in Dialysis (HD & PD) ▪️Evidence Gap Alert: While SGLT2 inhibitors robustly reduce CKD progression, CV events, and mortality in non-dialysis CKD, patients on dialysis (HD/PD) were excluded from all landmark RCTs, creating a major evidence void. ▪️Mechanistic Shift in ESKD: In dialysis patients, classical glucosuric/tubular effects are minimal due to low nephron mass; benefits are likely mediated via cardio-metabolic off-target pathways (↓ inflammation, ↓ oxidative stress, improved myocardial energetics). ▪️Pharmacokinetic Reassurance: Dapagliflozin is not dialyzable and does not accumulate significantly in dialysis patients—supporting biological plausibility for safe use. ▪️Signal from Early Data: Small trials and observational cohorts suggest potential CV benefit, improved volume status, and preservation of residual kidney function, particularly in incremental dialysis—without major safety signals. ▪️Peritoneal Dialysis Uncertainty: In PD, evidence is sparse and inconsistent—some studies show ↑ ultrafiltration and ↓ BP, while others show no effect on peritoneal glucose transport. ▪️Real-World Cohort Insight: Retrospective analyses indicate lower CV events and mortality in dialysis patients using SGLT2i, but these are hypothesis-generating, not definitive. ▪️Safety Perspective: No major red flags so far, but risk of volume depletion, hypotension, and rare euglycemic ketoacidosis warrants cautious patient selection. ▪️Clinical Position Today: Routine use in dialysis cannot be recommended yet; use should be individualized and preferably within research settings or expert supervision. ▪️Future Direction: Ongoing large RCTs are critical to define efficacy, safety, and patient selection—this could expand SGLT2i use into ESKD therapeutics beyond glycemia. 💢Take-Home Message: 👉 SGLT2 inhibitors in dialysis represent a promising but unproven frontier—mechanistically attractive, observationally encouraging, but awaiting definitive trial evidence before mainstream adoption. academic.oup.com/ckj/article/19…

IgA nephropathy progresses to kidney failure in up to 50% of patients within 10–20 years. On March 29th, the NEJM published the final 24-month data from APPLAUSE-IgAN and the results change the treatment landscape. Here’s what every nephrologist needs to know 🧵 Barratt J et al. NEJM 2026. DOI: 10.1056/NEJMoa2600743

In the setting of the alarming rise in worldwide disasters @ISNkidneycare @ASNKidney @ERAkidney are focusing on joint and impactful actions @ISNWCN #ISNWCN great talk by @Abualfaa from @AUB_Lebanon

Bacterial infection–associated glomerulonephritis in action 🔬🦠 Diffuse neutrophilic endocapillary proliferation, dominant C3 staining on IF, and classic subepithelial “hump-like” deposits on EM—hallmarks of infection-related GN. 💡 Key facts:
• Typically follows staph or strep infections (not just post-strep anymore)
• Often presents with AKI, hematuria, proteinuria
• Low complement (especially C3) is common
• IF: C3-dominant or co-dominant staining
• EM: subepithelial humps = immune complex deposition
• Can occur in adults with ongoing infection (not always “post”) Treat the infection → kidneys often follow.

Join GlomCon this Sunday The Podocytopathies: Current Concepts in Pathogenesis, guidelines, Novel therapies by Dr. Jai Radhakrishnan ID: 817 4374 4653 Passcode: 202122 Sign up 👉🏻 bit.ly/signup-glomcon #Glomcon